Skip to main content
AmigoFish

EP 265: How blood biomarkers are changing neurology diagnostics with Joe Volpe of Labcorp

From The Genetics Podcast · · 42 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

This week on The Genetics Podcast, Patrick is joined by Dr. Joe Volpe, Executive Director, Scientific Strategy & Commercialization at Labcorp. They discuss how blood biomarkers like p-tau217 are changing Alzheimer’s diagnosis, which biomarkers are emerging in Parkinson’s disease and ALS, and what Labcorp’s real-world testing data reveals about how physicians use these tests.

Show Notes

0:00 Intro to The Genetics Podcast

00:58 Welcome to Joe

01:47 Joe’s career in HIV genetics and his move into neurology

06:35 Alzheimer’s blood biomarkers, beta amyloid, and the rise of p-tau217

11:04 Why p-tau217 works as a scalable Alzheimer’s blood test

12:35 How p-tau217 triages patients and what it can’t tell clinicians

14:08 APOE testing demand and why it predicts risk without being definitive

17:46 Where Alzheimer’s treatment and early detection go next, and what is still unknown

21:26 How Parkinson’s and ALS diagnostics are following the path Alzheimer’s took

24:09 Neurofilament light (NfL), peripherin, and DDC as emerging ALS and Parkinson’s biomarkers

27:04 Where DDC fits in Parkinson’s diagnosis compared with p-tau217

29:30 How Labcorp’s real-world testing data shows what NfL and p-tau217 are used for

34:27 How Labcorp decides which neurology biomarkers to launch and when

38:12 Future potential for migraine biomarkers that can guide treatment choices

41:07 Closing remarks

Back to The Genetics Podcast · Report a problem